Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes (Q34763641)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes (English)

1 reference

Europe PubMed Central

4 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Myriam Locatelli-Sanchez

1

1 reference

Europe PubMed Central

4 August 2017

Sébastien Couraud

2

1 reference

Europe PubMed Central

4 August 2017

Dominique Arpin

3

1 reference

Europe PubMed Central

4 August 2017

Robert Riou

4

1 reference

Europe PubMed Central

4 August 2017

Pierre-Paul Bringuier

5

1 reference

Europe PubMed Central

4 August 2017

Pierre-Jean Souquet

6

1 reference

Europe PubMed Central

4 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 June 2013

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

191

1 reference

Europe PubMed Central

4 August 2017

5

1 reference

Europe PubMed Central

4 August 2017

491-499

1 reference

Europe PubMed Central

4 August 2017

https://scigraph.springernature.com/pub.10.1007/s00408-013-9482-4

0 references

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

A simple view on lung cancer biology: The EGFR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Screening for EGFR mutations in lung cancer, a report from India.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

[What is the best sequence of treatment for patients with EGFR mutations?].

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Tumour molecular profiling for deciding therapy-the French initiative.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status f

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00408-013-9482-4

1 reference

Europe PubMed Central

4 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34763641&oldid=1988770822"